Cargando…
Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience
We report on manufacturing outcomes for 41 autologous polyclonal regulatory T cell (PolyTreg) products for 7 different Phase 1 clinical trials over a 10-year period (2011-2020). Data on patient characteristics, manufacturing parameters, and manufacturing outcomes were collected from manufacturing ba...
Autores principales: | Balcerek, Joanna, Shy, Brian R., Putnam, Amy L., Masiello, Lisa M., Lares, Angela, Dekovic, Florinna, Acevedo, Luis, Lee, Michael R., Nguyen, Vinh, Liu, Weihong, Paruthiyil, Sreenivasan, Xu, Jingying, Leinbach, Ashley S., Bluestone, Jeffrey A., Tang, Qizhi, Esensten, Jonathan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636860/ https://www.ncbi.nlm.nih.gov/pubmed/34867967 http://dx.doi.org/10.3389/fimmu.2021.744763 |
Ejemplares similares
-
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
por: Dong, Shen, et al.
Publicado: (2021) -
NO/cGMP signalling in platelets
por: Schinner, Elisabeth, et al.
Publicado: (2009) -
cGMP and cardiac hypertrophy
por: Perera, Ruwan K, et al.
Publicado: (2015) -
Analysis of cGMP signalling with transgenic mice expressing FRET-based cGMP sensors
por: Wen, Lai, et al.
Publicado: (2013) -
Transient kinetics of a cGMP-dependent cGMP-specific phosphodiesterase from Dictyostelium discoideum
Publicado: (1984)